CRITICAL STAGES Sample Clauses

CRITICAL STAGES. The Contractor shall achieve critical stages of the Work in accordance with the following requirements:
AutoNDA by SimpleDocs
CRITICAL STAGES. D16.1 The Contractor shall achieve critical stages of the Work in accordance with the following requirements: (a) Installation of the land drainage sewers, final pavement and boulevard restorations on Ness Avenue between Queen Street and Madison Street by October 30, 2013. (b) Installation of land drainage sewers, temporary pavement restoration on the remainder of Ness Avenue, west of Queen Street by November 30, 2013.
CRITICAL STAGES. D14.1 The Contractor shall achieve critical stages of the Work in accordance with the following requirements: (a) October 15, 2017 – End of Cell 31 geomembrane installation- The installation of the synthetic liner (HDPE geomembrane) in Cell 31 must be completed in accordance with the manufacturer recommendations and the Landfill’s Environment Act Licence No. 3081R. (b) November 15, 2017 – End of Cell 31 Construction - The construction of Cell 31 must be completed by this date. The completion of the Cell 31 construction includes the excavation to required grades, re-compaction of clay surface, placement and testing of geomembrane and geotextiles, placement and testing of leachate collection pipes, installation of vertical manhole in sump for leachate collection, placement of leachate drainage material to final grades and all mechanical and electrical appurtenances related to final operation.
CRITICAL STAGES. D18.1 The Contractor shall achieve critical stages of the Work in accordance with the following requirements: (a) Dewatering of the 1500 mm Brooklands-Xxxxxx Land Drainage Trunk Sewer and completion of the installation of manhole base sections up to elevation 229.0 m to be completed by March 1, 2015. (b) Completion of all works east of Century Street (St. Xxxxxxxx Avenue, Kensington Street, Madison Street) excluding final surface restoration by May 1, 2015, to avoid conflict with works by others.
CRITICAL STAGES. D17.1 The Contractor shall achieve critical stages of the Work in accordance with the following requirements: (a) Installation of outfall, sewer works, rip rap and all river works in Xxx Xxxxx Park and Installation of new flap gate at Ness Avenue and Xxxxxx Street gate chamber completed before completed before March 15, 2017. (b) Installation of new flap gate at Ness Avenue and Xxxxxx Street completed before March 15, 2017. Testing of gate may occur after the spring flood has passed.
CRITICAL STAGES. D17.1 The Contractor shall achieve critical stages of the Work in accordance with the following requirements: (a) Installation of sewers and restoration of pavement and boulevards on Winston Road completed before September 4, 2017.

Related to CRITICAL STAGES

  • Weaknesses By far the biggest weakness in Dundee is the high concentration of deprivation. Of the 179 datazones in the city 53(30%) including 28.9% of the population are in the 15% most deprived according to the Scottish Index of Multiple Deprivation. The effect of this level of inequality is that Dundee has outcomes in relation to learning, health and employability which are significantly lower than the Scottish average.

  • Critical Illness Three (3) days per year, with pay, shall be granted in the case of a critical illness or accident to a member of the employee's immediate family as defined in Section 9.4.2. A statement by the physician verifying the need for the employee to be present with the immediate family member shall be attached to the absence form.

  • Critical Accounting Policies The section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Time of Sale Prospectus and the Prospectus accurately and fairly describes (i) the accounting policies that the Company believes are the most important in the portrayal of the Company’s financial condition and results of operations and that require management’s most difficult subjective or complex judgment; (ii) the material judgments and uncertainties affecting the application of critical accounting policies and estimates; (iii) the likelihood that materially different amounts would be reported under different conditions or using different assumptions and an explanation thereof; (iv) all material trends, demands, commitments and events known to the Company, and uncertainties, and the potential effects thereof, that the Company believes would materially affect its liquidity and are reasonably likely to occur; and (v) all off-balance sheet commitments and arrangements of the Company and its Controlled Entities, if any. The Company’s directors and management have reviewed and agreed with the selection, application and disclosure of the Company’s critical accounting policies as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus and have consulted with its independent accountants with regards to such disclosure.

  • Statistical Sampling Documentation a. A copy of the printout of the random numbers generated by the “Random Numbers” function of the statistical sampling software used by the IRO.‌ b. A description or identification of the statistical sampling software package used by the IRO.‌

  • Technical Reports All technical reports are to be prepared jointly by the Recipient/Institution conducting Work and all collaborating institutions or as deemed acceptable by the Centre’s contact.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Technical Objections to Grievances It is the intent of both Parties of this Agreement that no grievance shall be defeated merely because of a technical error, other than time limitations in processing the grievance through the grievance procedure. To this end, an arbitration board shall have the power to allow all necessary amendments to the grievance and the power to waive formal procedural irregularities in the processing of a grievance, in order to determine the real matter in dispute and to render a decision according to equitable principles and the justice of the case.

  • Development Reports Beginning six months after Effective Date and ending on the date of first commercial sale of a Licensed Product in the United States, LICENSEE shall report to Cornell progress covering LICENSEE's (and Affiliate's and Sublicensee's) activities and efforts in the development of rights granted to LICENSEE under this Agreement for the preceding six months. The report shall include, but not be limited to, activities and efforts to develop and test all Licensed Products and obtain governmental approvals necessary for marketing the same. Such semi-annual reports shall be due within sixty days (60) of the reporting period and shall use the form as provided herein as Appendix C.

  • Financial Statements Statistical Data 2.6.1. The financial statements, including the notes thereto and supporting schedules included in the Registration Statement and the Prospectus, fairly present the financial position and the results of operations of the Company at the dates and for the periods to which they apply. Such financial statements have been prepared in conformity with generally accepted accounting principles of the United States, consistently applied throughout the periods involved, and the supporting schedules included in the Registration Statement present fairly the information required to be stated therein. No other financial statements or supporting schedules are required to be included in the Registration Statement. The Registration Statement discloses all material off-balance sheet transactions, arrangements, obligations (including contingent obligations), and other relationships of the Company with unconsolidated entities or other persons that may have a material current or future effect on the Company's financial condition, changes in financial condition, results of operations, liquidity, capital expenditures, capital resources, or significant components of revenues or expenses. There are no pro forma or as adjusted financial statements which are required to be included in the Registration Statement and the Prospectus in accordance with Regulation S-X which have not been included as so required. 2.6.2. The statistical, industry-related and market-related data included in the Registration Statement and the Prospectus are based on or derived from sources which the Company reasonably and in good faith believes are reliable and accurate, and such data agree with the sources from which they are derived.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!